Leukemia Research
Volume 27, Issue 6 , Pages 471-473 , June 2003

Commentary: effect of flavonoids on normal and leukemic cells

  • Stefan Faderl

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, P.O. Box 428, 1515 Holcombe Blvd., Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-713-745-4613; fax: +1-713-794-4297.
    • ,
  • Zeev Estrov

      Affiliations

    • Department of Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, P.O. Box 428, 1515 Holcombe Blvd., Houston, TX 77030, USA

Received 29 October 2002 ,Accepted 30 October 2002.

References 

  1. Mauro MJ, O’Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J. Clin. Oncol. 2002;20:325
  2. Zhai A, Senderowicz AM, Sausville EA, Figg WD. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. New Drug Dev. 2002;36:905
  3. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 2000;92:376
  4. Parker BW, Kaur G, Nieves-Neira W, Taimi W, Kohlhagen G, Shimizu T, et al.  Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood. 1998;91:458
  5. Bible KC, Bible RH, Kottke TJ, Svingen PA, Xu K, Pang YP, et al.  Flavopiridol binds to duplex DNA. Cancer Res. 2000;60:2419
  6. Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, et al.  Downregulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 1999;59:4634
  7. Melillo G, Sausville EA, Cloud K, Lahusen T, Varresio L, Senderowicz A. Flavopiridol, a potent kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res. 1999;59:5433
  8. Liesveld JL, Abboud CN, Lu C, McNair II C, Menon A, Smith A, et al. Flavonoid effects on normal and leukemic cells. Leuk Res.
  9. Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Blood. 1997;89:243
  10. Alexander WS, Starr R, Metcalf D, et al.  Suppressors of cytokine signaling (SOCS): negative regulators of signal transduction. J. Leuk. Biol. 1999;66:588
  11. Sakai I, Takeuchi K, Yamauchi H, et al.  Constitutive expression of SOCS3 confers resistance to INF-α in chronic myelogenous leukemia. Blood. 2002;100:2926
  12. Senderowicz AM, Headlee D, Stinson SF, et al.  Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol. 1998;16:2986
  13. Senderowicz AM, Messmann R, Arbuck S, et al. A phase trial of 1 hour infusion of flavopiridol (FLA), a novel cyclin-dependent kinase inhibitor, in patients with advanced neoplasms. Proc Am Soc Clin Oncol 2000;204a.
  14. Yu C, Krystal G, Dent P, Grant S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR–ABL-positive human leukemia cells. Clin. Cancer Res. 2002;8:2976
  15. Almenara J, Rosato R, Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deactylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia. 2002;16:1331

PII: S0145-2126(02)00276-X

doi: 10.1016/S0145-2126(02)00276-X

Leukemia Research
Volume 27, Issue 6 , Pages 471-473 , June 2003

Article Tools